Download PDF
Onkologische Welt 2022; 13(02): 96-98
DOI: 10.1055/a-1774-3860
Kongressnachlese

Mammakarzinom

Therapieoptimierung durch Kombination verschiedener Wirkstrategien
Ine Schmale
1   Westerburg
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

In der Behandlung des Mammakarzinoms haben sich u. a. die endokrine Therapie, die PARP-Inhibitoren und die CDK4/6-Inhibitoren etabliert. Beim vergangenen San Antonio Breast Cancer Symposium (SABCS) wurden neue Untersuchungen zu bewährten Therapien präsentiert.



Publication History

Article published online:
20 May 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 O´Shaughnessy, et al Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR + /HER2- breast cancer. SABCS. 2021: Abstract GS1-02
    Google Scholar
  • 2 Bianchini G. et al Circulating tumor DNA (ctDNA) dynamic in patients with HR + /HER2- advanced breast cancer treated in first line with ribociclib and letrozole in the BioltaLEE trial. SABCS. 2021: Abstract GS3-07
    Google Scholar
  • 3 Gnant M. et al Adjuvant palbociclib in HR + /HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. SABCS. 2021: Abstract GS1-07
    Google Scholar
  • 4 Ganz P. et al Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2- early breast cancer. SABCS. 2021: Abstract GS4-09
    Google Scholar